Display options
Cite
Shen S, Wei Y, Zhang R, et al. Mutant-allele fraction heterogeneity is associated with non-small cell lung cancer patient survival. Oncol Lett. 2017;15(1):795-802doi: 10.3892/ol.2017.7428.
Shen, S., Wei, Y., Zhang, R., Du, M., Duan, W., Yang, S., Zhao, Y., Christiani, D. C., & Chen, F. (2018). Mutant-allele fraction heterogeneity is associated with non-small cell lung cancer patient survival. Oncology letters, 15(1), 795-802. https://doi.org/10.3892/ol.2017.7428
Shen, Sipeng, et al. "Mutant-allele fraction heterogeneity is associated with non-small cell lung cancer patient survival." Oncology letters vol. 15,1 (2018): 795-802. doi: https://doi.org/10.3892/ol.2017.7428
Shen S, Wei Y, Zhang R, Du M, Duan W, Yang S, Zhao Y, Christiani DC, Chen F. Mutant-allele fraction heterogeneity is associated with non-small cell lung cancer patient survival. Oncol Lett. 2018 Jan;15(1):795-802. doi: 10.3892/ol.2017.7428. Epub 2017 Nov 15. PMID: 29399148; PMCID: PMC5772758.
Copy Download .nbib Format: NLM
Share it on

Oncol Lett. 2018 Jan;15(1):795-802. doi: 10.3892/ol.2017.7428. Epub 2017 Nov 15.

Mutant-allele fraction heterogeneity is associated with non-small cell lung cancer patient survival.

Oncology letters

Sipeng Shen, Yongyue Wei, Ruyang Zhang, Mulong Du, Weiwei Duan, Sheng Yang, Yang Zhao, David C Christiani, Feng Chen

Affiliations

  1. Department of Biostatistics, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu 211136, P.R. China.
  2. Department of Environmental Health, Harvard School of Public Health, Boston, MA 02115, USA.
  3. Ministry of Education Key Laboratory for Modern Toxicology, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu 211166, P.R. China.

PMID: 29399148 PMCID: PMC5772758 DOI: 10.3892/ol.2017.7428

Abstract

Genetic intratumor heterogeneity is associated with tumor occurrence, development and overall outcome. The present study aims to explore the association between mutant-allele fraction (MAF) heterogeneity and patient overall survival in lung cancer. Somatic mutation data of 939 non-small cell lung cancer (NSCLC) cases were obtained from The Cancer Genome Atlas. Entropy-based mutation allele fraction (EMAF) score was used to describe the uncertainty of individual somatic mutation patterns and to further analyze the association with patient overall survival. Results indicated that association between EMAF and overall survival was significant in the discovery set [hazard ratio (H)R=1.62; 95% confidence interval (CI): 1.08-2.41; P=0.018] and replication set (HR=1.63; 95% CI: 1.11-2.37; P=0.011). In addition, EMAF was also significantly different in lung adenocarcinoma and squamous cell carcinoma. Furthermore, a significant difference was indicated in early-stage patients. Results from c-index analysis indicated that EMAF improved the model predictive performance on the 3-year survival beyond that of traditional clinical staging, particularly in early-stage patients. In conclusion, EMAF successfully reflected MAF heterogeneity among patients with NSCLC. Additionally, EMAF improved the predictive performance in early-stage patient prognosis beyond that of traditional clinical staging. In clinical application, EMAF appears to identify a subset of early-stage patients with a poor prognosis and therefore may help inform clinical decisions regarding the application of chemotherapy after surgery.

Keywords: information entropy; mutant-allele fraction heterogeneity; non-small cell lung cancer; overall survival

References

  1. MD Comput. 1997 Jul-Aug;14(4):306-17 - PubMed
  2. Clin Genet. 2011 Aug;80(2):101-3 - PubMed
  3. Tumour Biol. 2013 Jun;34(3):1641-50 - PubMed
  4. Science. 2014 Oct 10;346(6206):256-9 - PubMed
  5. Head Neck Pathol. 2015 Mar;9(1):1-5 - PubMed
  6. Nat Commun. 2016 Aug 16;7:12474 - PubMed
  7. Cancer Res. 1984 Jun;44(6):2259-65 - PubMed
  8. Nature. 2011 Apr 7;472(7341):90-4 - PubMed
  9. Oral Oncol. 2013 Mar;49(3):211-5 - PubMed
  10. Bioinformatics. 2009 Sep 1;25(17):2283-5 - PubMed
  11. Acta Pathol Microbiol Scand A. 1974 Jan;82(1):35-40 - PubMed
  12. Swiss Med Wkly. 2015 Sep 16;145:w14183 - PubMed
  13. Science. 2014 Jun 20;344(6190):1396-401 - PubMed
  14. Lung Cancer. 2016 Sep;99:200-7 - PubMed
  15. Cell. 2013 Feb 14;152(4):714-26 - PubMed
  16. Nature. 2011 Mar 24;471(7339):467-72 - PubMed
  17. Mol Biosyst. 2015 Jan;11(1):126-36 - PubMed
  18. Stat Med. 2011 May 10;30(10):1105-17 - PubMed
  19. Oncol Lett. 2013 Sep;6(3):763-768 - PubMed
  20. Cancer Res. 1978 Oct;38(10):3174-81 - PubMed
  21. PLoS Med. 2015 Feb 10;12(2):e1001786 - PubMed
  22. Lancet Oncol. 2015 Jul;16(7):e342-51 - PubMed
  23. Science. 2014 Oct 10;346(6206):251-6 - PubMed
  24. Ann Oncol. 2016 Feb;27(2):240-8 - PubMed
  25. Nature. 2014 Jul 31;511(7511):543-50 - PubMed
  26. PLoS One. 2013 Jul 18;8(7):e69321 - PubMed
  27. Br J Cancer. 2011 Jan 18;104(2):361-8 - PubMed
  28. Cancer. 2013 Aug 15;119(16):3034-42 - PubMed
  29. Lung Cancer. 2011 Nov;74(2):164-9 - PubMed
  30. N Engl J Med. 2012 Mar 8;366(10 ):883-892 - PubMed
  31. Presse Med. 2012 Jun;41(6 Pt 1):e250-6 - PubMed
  32. Lancet. 2017 Jan 21;389(10066):299-311 - PubMed
  33. Nat Rev Genet. 2014 Sep;15(9):574-5 - PubMed
  34. Science. 1976 Oct 1;194(4260):23-8 - PubMed
  35. Phys Rev Lett. 2000 Jul 10;85(2):461-4 - PubMed
  36. Science. 1977 Aug 26;197(4306):893-5 - PubMed

Publication Types

Grant support